Metformin pharmacogenomics: current status and future directions

The incidence of type 2 diabetes (T2D) and its costs to the health care system continue to rise. Despite the availability of at least 10 drug classes for the treatment of T2D, metformin remains the most widely used first-line pharmacotherapy for its treatment; however, marked interindividual variabi...

Celý popis

Podrobná bibliografia

Vydané v:	Diabetes (New York, N.Y.) Ročník 63; číslo 8; s. 2590
Hlavní autori:	Pawlyk, Aaron C, Giacomini, Kathleen M, McKeon, Catherine, Shuldiner, Alan R, Florez, Jose C
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.08.2014
Predmet:	Adolescent Adult Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - genetics Gene Expression Regulation Humans Hypoglycemic Agents - adverse effects Hypoglycemic Agents - metabolism Hypoglycemic Agents - therapeutic use Metformin - adverse effects Metformin - metabolism Metformin - therapeutic use Pharmacogenetics
ISSN:	1939-327X, 1939-327X
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!